179 related articles for article (PubMed ID: 33392972)
1. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib.
Alkebsi L; Wang X; Ohkawara H; Fukatsu M; Mori H; Ikezoe T
Int J Hematol; 2021 Mar; 113(3):441-455. PubMed ID: 33392972
[TBL] [Abstract][Full Text] [Related]
2. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
3. cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
Aoyama T; Kuriyama H; Sato Y; Imai S; Kashiwagi H; Sugawara M; Takekuma Y
Biol Pharm Bull; 2021; 44(8):1101-1110. PubMed ID: 34334496
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein A1 Inhibits the TGF-β1-Induced Endothelial-to-Mesenchymal Transition of Human Coronary Artery Endothelial Cells.
Feng J; Zhang J; Jackson AO; Zhu X; Chen H; Chen W; Gui Q; Yin K
Cardiology; 2017; 137(3):179-187. PubMed ID: 28434000
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
8. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
9. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Ozanne J; Prescott AR; Clark K
Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21.
Kumarswamy R; Volkmann I; Jazbutyte V; Dangwal S; Park DH; Thum T
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):361-9. PubMed ID: 22095988
[TBL] [Abstract][Full Text] [Related]
11. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
12. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
[TBL] [Abstract][Full Text] [Related]
13. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
16. High glucose induced endothelial to mesenchymal transition in human umbilical vein endothelial cell.
Yu CH; Suriguga ; Gong M; Liu WJ; Cui NX; Wang Y; Du X; Yi ZC
Exp Mol Pathol; 2017 Jun; 102(3):377-383. PubMed ID: 28347704
[TBL] [Abstract][Full Text] [Related]
17. TGF-β1-induced SMAD2/3/4 activation promotes RELM-β transcription to modulate the endothelium-mesenchymal transition in human endothelial cells.
Jiang Y; Zhou X; Hu R; Dai A
Int J Biochem Cell Biol; 2018 Dec; 105():52-60. PubMed ID: 30120989
[TBL] [Abstract][Full Text] [Related]
18. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
19. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p.
Sukegawa M; Wang X; Nishioka C; Pan B; Xu K; Ohkawara H; Hamasaki Y; Mita M; Nakamura K; Okamoto M; Shimura H; Ohta M; Ikezoe T
Leuk Res; 2017 Jul; 58():83-90. PubMed ID: 28501737
[TBL] [Abstract][Full Text] [Related]
20. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
Miura M; Takahashi N
Rinsho Ketsueki; 2019; 60(9):1140-1147. PubMed ID: 31597837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]